2020
Ranganath, L. R., Psarelli, E. E., Arnoux, J. -B., Braconi, D., Briggs, M., Broijersen, A., . . . Gallagher, J. A. (2020). Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. The Lancet Diabetes and Endocrinology, 8(9), 762-772. doi:10.1016/S2213-8587(20)30228-XDOI: 10.1016/S2213-8587(20)30228-X
Khedr, M., Cooper, M. S., Hughes, A. T., Milan, A. M., Davison, A. S., Norman, B. P., . . . Ranganath, L. R. (2020). Nitisinone causes acquired tyrosinosis in alkaptonuria. JOURNAL OF INHERITED METABOLIC DISEASE, 43(5), 1014-1023. doi:10.1002/jimd.12229DOI: 10.1002/jimd.12229
Halloran, C. M. (n.d.). Prognostic value of 18FDG PET-CT volumetric parameters in the survival prediction of patients with pancreatic cancer. Annals of Surgical Oncology. doi:10.1016/j.ejso.2020.02.002DOI: 10.1016/j.ejso.2020.02.002
Ranganath, L. R., Milan, A. M., Hughes, A. T., Khedr, M., Davison, A. S., Shweihdi, E., . . . Gallagher, J. A. (2020). Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria. JOURNAL OF INHERITED METABOLIC DISEASE, 43(4), 737-747. doi:10.1002/jimd.12181DOI: 10.1002/jimd.12181
Judd, S., Khedr, M., Milan, A. M., Davison, A. S., Hughes, A. T., Needham, A., . . . Ranganath, L. R. (2020). The nutritional status of people with alkaptonuria: An exploratory analysis suggests a protein/energy dilemma.. JIMD reports, 53(1), 45-60. doi:10.1002/jmd2.12084DOI: 10.1002/jmd2.12084
2019
Jones, R. P., Psarelli, E. -E., Jackson, R., Ghaneh, P., Halloran, C. M., Palmer, D. H., . . . Millat, B. (2019). Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA SURGERY, 154(11), 1038-1048. doi:10.1001/jamasurg.2019.3337DOI: 10.1001/jamasurg.2019.3337
Cox, T., Psarelli, E. E., Taylor, S., Shepherd, H. R., Robinson, M., Barton, G., . . . Ranganath, L. (2019). Subclinical ochronosis features in alkaptonuria: A cross-sectional study. BMJ Innovations. doi:10.1136/bmjinnov-2018-000324DOI: 10.1136/bmjinnov-2018-000324
Milan, A. M., Hughes, A. T., Davison, A. S., Khedr, M., Rovensky, J., Psarelli, E. E., . . . Ranganath, L. R. (2019). Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria. SCIENTIFIC REPORTS, 9. doi:10.1038/s41598-019-46033-xDOI: 10.1038/s41598-019-46033-x
2018
Griffin, R., Psarelli, E. E., Cox, T. F., Khedr, M., Milan, A. M., Davison, A. S., . . . Ranganath, L. R. (2018). Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone.. Data in Brief, 20, 1620-1628. doi:10.1016/j.dib.2018.09.021DOI: 10.1016/j.dib.2018.09.021
Ranganath, L. R., Khedr, M., Milan, A. M., Davison, A. S., Hughes, A. T., Usher, J. L., . . . Gallagher, J. A. (2018). Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Molecular genetics and metabolism, 125(1-2), 127-134. doi:10.1016/j.ymgme.2018.07.011DOI: 10.1016/j.ymgme.2018.07.011
Jackson, R., Psarelli, E., Berhane, S., & Johnson, P. J. (2018). Predictors of sorafenib benefit in patients with hepatocellular carcinoma. Journal of Hepatology, 68(3), 619-620. doi:10.1016/j.jhep.2017.09.028DOI: 10.1016/j.jhep.2017.09.028
2017
Reply to N. Personeni et al (Journal article)
Jackson, R., Psarelli, E., & Johnson, P. J. (2017). Reply to N. Personeni et al. Journal of Clinical Oncology, 35(19), 2214. doi:10.1200/JCO.2017.72.9293DOI: 10.1200/JCO.2017.72.9293
Psarelli, E. E., Jackson, R., Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Halloran, C. M., & Buechler, M. W. (2017). Beyond ESPAC-4: better surgery and systemic therapy. LANCET, 389(10078), 1517-1518. doi:10.1016/S0140-6736(17)30947-9DOI: 10.1016/S0140-6736(17)30947-9
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. (Journal article)
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., . . . Büchler, M. W. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.. Lancet (London, England), 389(10073), 1011-1024. doi:10.1016/s0140-6736(16)32409-6DOI: 10.1016/s0140-6736(16)32409-6
Jackson, R., Psarelli, E. E., Berhane, S., Khan, H., & Johnson, P. J. (2017). Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. Journal of Clinical Oncology, 35(6), 622-628. doi:10.1200/JCO.2016.69.5197DOI: 10.1200/JCO.2016.69.5197
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy (Journal article)
Bird, N. T. E., Elmasry, M., Jones, R., Psarelli, E., Dodd, J., Malik, H., . . . Palmer, D. (2017). Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. BRITISH JOURNAL OF SURGERY, 104(4), 328-336. doi:10.1002/bjs.10482DOI: 10.1002/bjs.10482
2016
ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma (Journal article)
Neoptolemos, J., Palmer, D., Ghaneh, P., Valle, J. W., Cunningham, D., Wadsley, J., . . . Büchler, M. (2016). ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Pancreatology, 16(3), S63. doi:10.1016/j.pan.2016.05.215DOI: 10.1016/j.pan.2016.05.215
Identification of malignant transformation within pancreatic IPMN: A systematic review and meta-analyses (Journal article)
Halloran, C., Jackson, R., Gilbert, T., Psarelli, E., Cox, T., Sutton, R., . . . Neoptolemos, J. (2016). Identification of malignant transformation within pancreatic IPMN: A systematic review and meta-analyses. Pancreatology, 16(3), S99. doi:10.1016/j.pan.2016.05.333DOI: 10.1016/j.pan.2016.05.333
Validation of preoperative cardiopulmonary exercise testing-derived variables to predict in-hospital morbidity after major colorectal surgery. (Journal article)
West, M. A., Asher, R., Browning, M., Minto, G., Swart, M., Richardson, K., . . . Perioperative Exercise Testing and Training Society. (2016). Validation of preoperative cardiopulmonary exercise testing-derived variables to predict in-hospital morbidity after major colorectal surgery.. The British journal of surgery, 103(6), 744-752. doi:10.1002/bjs.10112DOI: 10.1002/bjs.10112
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment (Journal article)
Ranganath, L. R., Milan, A. M., Hughes, A. T., Dutton, J. J., Fitzgerald, R., Briggs, M. C., . . . Rovensky, J. (2016). Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Annals of Rheumatic Disease, 75(2), 362-367. doi:10.1136/annrheumdis-2014-206033DOI: 10.1136/annrheumdis-2014-206033
2015
Sultana, A., Jackson, R., Gilbert, T., Bostock, E., Psarelli, E., Cox, T., . . . Halloran, C. (2015). What Is the Best Way to Identify MalignantTransformation Within Pancreatic IPMN: A SystematicReview and Meta-Analyses. Clinical and Translational Gastroenterology, 6(12), e130. doi:10.1038/ctg.2015.60DOI: 10.1038/ctg.2015.60
Colonoscopy performance is stable during the course of an extended three-session working day (Journal article)
Subramanian, S., Psarelli, E. E., Collins, P., Haslam, N., O'Toole, P., Lombard, M., & Sarkar, S. (2015). Colonoscopy performance is stable during the course of an extended three-session working day. ENDOSCOPY INTERNATIONAL OPEN, 3(5), E494-E500. doi:10.1055/s-0034-1392523DOI: 10.1055/s-0034-1392523
Diagnostic tools and strategies for assessing disease progression in Alkaptonuria (Journal article)
Ranganath, L. R., Psarelli, E. E., Cox, T. F., & Gallagher, J. A. (2015). Diagnostic tools and strategies for assessing disease progression in Alkaptonuria. EXPERT OPINION ON ORPHAN DRUGS, 3(6), 705-717. doi:10.1517/21678707.2015.1042859DOI: 10.1517/21678707.2015.1042859
The 5-year outcome of patients having incomplete colonoscopy (Journal article)
Britton, E. J., Sidhu, S., Geraghty, J., Psarelli, E., & Sarkar, S. (2015). The 5-year outcome of patients having incomplete colonoscopy. COLORECTAL DISEASE, 17(4), 298-303. doi:10.1111/codi.12901DOI: 10.1111/codi.12901
Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice. (Journal article)
Keenan, C. M., Preston, A. J., Sutherland, H., Wilson, P. J., Psarelli, E. E., Cox, T. F., . . . Gallagher, J. A. (2015). Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice. JIMD REPORTS, VOL 24, 24, 45-50. doi:10.1007/8904_2015_437DOI: 10.1007/8904_2015_437
Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria (Journal article)
Olsson, B., Cox, T. F., Psarelli, E. E., Szamosi, J., Hughes, A. T., Milan, A. M., . . . Ranganath, L. R. (2015). Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria. JIMD REPORTS, VOL 24, 24, 21-27. doi:10.1007/8904_2015_412DOI: 10.1007/8904_2015_412
2014
Enhanced Recovery in the Resection of Colorectal Liver Metastases (Journal article)
Dunne, D. F. J., Yip, V. S., Jones, R. P., McChesney, E. A., Lythgoe, D. T., Psarelli, E. E., . . . Fenwick, S. W. (2014). Enhanced Recovery in the Resection of Colorectal Liver Metastases. JOURNAL OF SURGICAL ONCOLOGY, 110(2), 197-202. doi:10.1002/jso.23616DOI: 10.1002/jso.23616
The role of ultrasound in the management of patients with occult groin hernias (Journal article)
Alabraba, E., Psarelli, E., Meakin, K., Quinn, M., Leung, M., Hartley, M., & Howes, N. (2014). The role of ultrasound in the management of patients with occult groin hernias. INTERNATIONAL JOURNAL OF SURGERY, 12(9), 918-922. doi:10.1016/j.ijsu.2014.07.266DOI: 10.1016/j.ijsu.2014.07.266
2013
SHOULD A PLASTIC OR A FULLY COVERED METAL STENT BE PLACED AT INDEX ERCP WHEN A PATIENT PRESENTS WITH JAUNDICE DUE TO A MALIGNANT DISTAL BILIARY STRICTURE? (Journal article)
McClements, D., Mahmood, S., Whelan, P., Psarelli, E. -E., Smart, H. L., Evans, J., . . . Sarkar, S. (2013). SHOULD A PLASTIC OR A FULLY COVERED METAL STENT BE PLACED AT INDEX ERCP WHEN A PATIENT PRESENTS WITH JAUNDICE DUE TO A MALIGNANT DISTAL BILIARY STRICTURE?. GUT, 62, A58. doi:10.1136/gutjnl-2013-304907.130DOI: 10.1136/gutjnl-2013-304907.130
Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design (Journal article)
Psarelli, E. E., Cox, T., & Ranganath, L. (2013). Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design. Trials, 14(Suppl 1), P29. doi:10.1186/1745-6215-14-s1-p29DOI: 10.1186/1745-6215-14-s1-p29